Overview

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Status:
Active, not recruiting

Trial end date:
2022-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the outcomes across the 4 different treatment groups. The investigators hope that this treatment will improve the ability to cure more patients with HL and also limit the long-term side effects from the treatment. Although eliminating radiation in cohort 4 will eliminate the risk for long-term side effects from radiation, it is also possible that with BV+AVD chemotherapy alone there may be an increased risk of the Hodgkin lymphoma coming back after initial treatment.

Phase:

N/A

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborators:

City of Hope Medical Center
Seagen Inc.
Seattle Genetics, Inc.
Stanford University
University of Rochester

Treatments:

Antibodies, Monoclonal
Brentuximab Vedotin
Dacarbazine
Doxorubicin
Liposomal doxorubicin
Vinblastine